Background: Refractoriness to platelet (PLT) transfusion is a feared, life-threatening complication in hematology-oncology patients. Despite increased PLT requirement and treatment costs, the clinical management is difficult and these patients had less favorable outcomes.
Case report: We report on the efficacy of the thrombopoietic agent romiplostim in a patient with acute myeloid leukemia with chemotherapy-induced transfusion-refractory thrombocytopenia.
Conclusion: Romiplostim could be very helpfull in the management of AML patients with transfusion refractory thrombocytopenia.
© 2011 American Association of Blood Banks.